Effect of sugammadex on long-term prognosis in patients undergoing kidney transplantation
10.3760/cma.j.cn131073.20221118.00404
- VernacularTitle:舒更葡糖钠对肾移植术患者远期预后的影响
- Author:
Diansheng WU
1
;
Hongbin ZHOU
;
Zhuodan WANG
;
Huansen HUANG
Author Information
1. 广州医科大学附属第二医院麻醉科，广州 510260
- Keywords:
Sugammadex;
Kidney transplantation;
Prognosis
- From:
Chinese Journal of Anesthesiology
2023;43(4):410-413
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the effect of sugammadex on the long-term prognosis in the patients undergoing kidney transplantation.Methods:American Society of Anesthesiologists Physical Status classification Ⅲ or Ⅳ patients of either sex, aged 18-64 yr, underwent donation after cardiac death renal transplantation from January 1, 2018 to October 31, 2021, were included in this study. Their clinical data were retrospectively analyzed, and then the patients were divided into 2 groups: sugammadex group (group S) and control group (group C). The complications at 1 yr after surgery and patient/graft survival at 1 and 3 yr after surgery were recorded.Results:A total of 645 patients were finally enrolled in this study, with 319 patients in group S and 326 patients in group C. There was no significant difference in the incidence of postoperative complications within 1 yr after surgery between two groups ( P>0.05). The overall patient survival rate at 1 and 3 yr after surgery were 94.7% and 92.8% respectively, and the death-censored graft survival at 1 and 3 yr after surgery were 94.4% and 89.4% respectively in group S. The overall patient survival rate at 1 and 3 yr after surgery were 96.6% and 94.7% respectively, and the death-censored graft survival at 1 and 3 yr after surgery were 93.9% and 88.6% respectively in group C. There was no significant difference in patient/graft survival rate between two groups ( P>0.05). Conclusions:Sugammadex has no obvious effect on the long-term prognosis in the patients undergoing kidney transplantation.
